Sponsor Pipeline

Sovargen Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
1
Active Trials
1
Recruiting
5
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-11 NCT07287202
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical…		 Recruitment opened
2026-08-11 NCT07287202
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical…		 Enrollment reduced: 15 -> 12 participants
2026-08-11 NCT07287202
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical…		 Trial arms changed: 1 -> 2
2026-08-11 NCT07287202
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical…		 date change Primary completion pushed: 2026-12 -> 2027-02
2026-08-11 NCT07287202
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical…		 date change Completion moved earlier: 2027-06 -> 2027-03
Active Trials by Phase
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT07287202 Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical… Focal Cortical Dysplasia Recruiting
Get alerts when Sovargen's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free